Shandong Keyuan Pharmaceutical Co. Ltd. A - Asset Resilience Ratio

Latest as of June 2025: 6.44%

Shandong Keyuan Pharmaceutical Co. Ltd. A (301281) has an Asset Resilience Ratio of 6.44% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Shandong Keyuan Pharmaceutical Co. Ltd. balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥103.29 Million
≈ $15.11 Million USD Cash + Short-term Investments

Total Assets

CN¥1.60 Billion
≈ $234.77 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2023–2024)

This chart shows how Shandong Keyuan Pharmaceutical Co. Ltd. A's Asset Resilience Ratio has changed over time. See 301281 net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Shandong Keyuan Pharmaceutical Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shandong Keyuan Pharmaceutical Co. Ltd. stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥103.29 Million 6.44%
Total Liquid Assets CN¥103.29 Million 6.44%

Asset Resilience Insights

  • Limited Liquidity: Shandong Keyuan Pharmaceutical Co. Ltd. A maintains only 6.44% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shandong Keyuan Pharmaceutical Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Shandong Keyuan Pharmaceutical Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AbbVie Inc
NYSE:ABBV
Drug Manufacturers - General 0.02%
Roche Holding AG
SW:ROG
Drug Manufacturers - General 15.37%
Biogen Inc
NASDAQ:BIIB
Drug Manufacturers - General 2.74%
CSPC Pharmaceutical Group Limited
F:CVG
Drug Manufacturers - General 4.64%
AstraZeneca PLC
LSE:AZN
Drug Manufacturers - General 0.03%
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
Drug Manufacturers - General 0.53%
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
Drug Manufacturers - General 5.37%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 10.10%

Annual Asset Resilience Ratio for Shandong Keyuan Pharmaceutical Co. Ltd. A (2023–2024)

The table below shows the annual Asset Resilience Ratio data for Shandong Keyuan Pharmaceutical Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 16.39% CN¥254.43 Million
≈ $37.23 Million
CN¥1.55 Billion
≈ $227.18 Million
+6.15pp
2023-12-31 10.24% CN¥150.54 Million
≈ $22.03 Million
CN¥1.47 Billion
≈ $215.10 Million
--
pp = percentage points

About Shandong Keyuan Pharmaceutical Co. Ltd. A

SHE:301281 China Drug Manufacturers - General
Market Cap
$597.24 Million
CN¥4.08 Billion CNY
Market Cap Rank
#11630 Global
#3551 in China
Share Price
CN¥37.69
Change (1 day)
-0.53%
52-Week Range
CN¥26.26 - CN¥50.45
All Time High
CN¥59.70
About

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clemastine fumarate; chlorpheniramine maleate; esmo… Read more